Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.

Hsien-Hong LinShih-Jer HsuSheng-Nan LuWan-Long ChuangChao-Wei HsuRong-Nan ChienSien-Sing YangWei-Wen SuJaw-Ching WuTzong-Hsi LeeCheng-Yuan PengKuan-Chiao TsengAlbert QinYi-Wen Huang Pei-Jer Chen

Published in: JGH open : an open access journal of gastroenterology and hepatology (2021)

Ropeginterferon alfa-2b showed longer effective half-life and superior safety profile than PEG-IFN-α2a. Biweekly injection of ropeginterferon alfa-2b will be studied in larger viral hepatitis patient population.

Keyphrases

replacement therapy
sars cov
immune response
case report
dendritic cells
smoking cessation
liver fibrosis